Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes.

Trial Profile

Effect of Liraglutide or Exenatide Added to a Background Treatment of Metformin, Sulphonylurea or a Combination of Both on Glycaemic Control in Subjects With Type 2 Diabetes.

Completed
Phase of Trial: Phase III

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Liraglutide (Primary) ; Exenatide
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Registrational; Therapeutic Use
  • Acronyms LEAD-6
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Jul 2016 Results of a meta-analysis in African-American/black people with T2DM from seven phase III trials (NCT00395746, NCT00614120, NCT00294723, NCT00333151, NCT00331851, NCT00518882 and NCT00700817), published in the Diabetic Medicine
    • 23 Jun 2012 Planned number of patients changed from 434 to 723 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top